Asset Details
Do you wish to reserve the book?
Pharmacological evaluation of newly synthesized organotin IV complex for antiulcer potential
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pharmacological evaluation of newly synthesized organotin IV complex for antiulcer potential
Do you wish to request the book?
Pharmacological evaluation of newly synthesized organotin IV complex for antiulcer potential
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pharmacological evaluation of newly synthesized organotin IV complex for antiulcer potential
2022
Overview
The present study aims to investigate the newly synthesized organotin (IV) complex (2E, 2′E) dibutylstannanediyl bis (4-(4-nitrophenyl) amino)-4-oxobut-2-enoate (DTN) for its anti-ulcer potential. Characterization performed by carbon nuclear magnetic resonance spectroscopy proved that all values are in the expected ranges of the new compound. Gastroprotective activity of DTN was evaluated through
in-silico,
anti-
H. pylori,
in-vitro
,
in-vivo, and ex-vivo proteomic analysis.
In-silico
analysis shows that DTN possess stable binding with protein targets involved in gastric ulcer pathophysiology. DTN exhibited an inhibitory effect against 2,2-diphenyl-1-picrylhydrazyl,
H. pylori
and hydrogen potassium ATPase (H
+
/K
+
-ATPase). The antiulcer activity was performed using an ethanol-induced gastric ulcer model in rats. Anti-oxidant profile of DTN showed a significant increase in glutathione-S-transferase, glutathione and catalase levels whereas lipid peroxidation levels were reduced. Histopathological findings confirmed that DTN protected the gastric mucosa of rats. Inflammatory markers tumor necrosis factor-alpha, nuclear factor kappa B, cyclooxygenase-2, interleukin 6 and interleukin-1β were reduced and prostaglandin-E
2
restored expression of these cytokines in DTN pretreated animals when analyzed by using immunohistochemistry, enzyme-linked immunosorbent assay and western blot techniques. In real-time polymerase chain reaction technique, the expression of H
+
/K
+
-ATPase was downregulated in DTN pretreated group. DTN did not cause any mortality up to 400 mg/Kg. This study indicates that the newly synthesized compound DTN, possess stable binding against selected targets. DTN exhibits a gastro-protective effect, mediated via anti-
H. pylori,
H
+
/K
+
-ATPase inhibition, anti-oxidant and anti-inflammatory pathways, exploring its therapeutic potential in gastric ulcer management.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
2E, 2′E) dibutylstannanediyl bis(4-((4-nitrophenyl) amino)-4-oxobut-2-enoate
/ Analysis
/ Animals
/ Anti-Ulcer Agents - pharmacology
/ Anti-Ulcer Agents - therapeutic use
/ Binding
/ Biomedical and Life Sciences
/ Catalase
/ Enzyme-linked immunosorbent assay
/ Ethanol
/ H(+)-K(+)-Exchanging ATPase - metabolism
/ Helicobacter pylori - metabolism
/ Hydrogen
/ IL-1β
/ Ligands
/ Lipids
/ Magnetic resonance spectroscopy
/ NMR
/ Nuclear magnetic resonance spectroscopy
/ Oxidants
/ Proteins
/ Proton Pump Inhibitors - pharmacology
/ Proton Pump Inhibitors - therapeutic use
/ Rats
/ Stomach Ulcer - chemically induced
/ Stomach Ulcer - drug therapy
/ Ulcers
